Any current/future new fundraising through debt or equity?

Currently, Sanjivani Paranteral Limited has no debt on its books and plans to maintain a debt-free status. There are no ongoing plans or requirements for new debt funding. Regarding equity or other funding for future investments, no additional funds are needed at present. Recent projects mentioned were funded earlier in January through a preferential equity raise, as disclosed in Stock Exchange documents. No immediate fundraising activities are planned since existing funds cover current projects, and no new opportunities requiring funding have been identified.

Any current/future capex/capital investment/strategic investment?

The company currently does not require additional funds for projects; recent investments were raised through a preferential raise in January. For the base business growth (around 20-25% YoY), no major incremental CAPEX is expected beyond ongoing maintenance and upgrades. Planned CAPEX of Rs. 10-12 crores is for basic upgrades and regulatory inspections, spread over this and next financial year, not as an annual recurring expense. The HAL Joint Venture has a development timeline of 9-12 months for production start, with commercial operations expected by October 2024. The Prague JV is partially

Future growth expectations in sales/revenue/volumes?

Base business expected to grow at approximately 25% year-on-year. HAL joint venture projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26. Prague joint venture operational with initial orders executed; full operational capacity expected by end of August or September 2024. Growth from strategic partnerships with five state PSUs and potential expansion via Public-Private Partnership (PPP) models. Expansion into new geographies including Africa, Central America, Middle East, and Latin America. Focus on complex products and higher value-addition segments, with plans to

Future growth expectations in earnings/operating earnings/profits/EPS?

Base business expected to grow at approximately 25% year-on-year. HAL JV projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26. Prague JV operational with order flow expected to increase post logistical issues resolution; guidance uncertain due to logistics. EBITDA margins impacted currently by high logistics costs but expected to improve as issues resolve. No major incremental CAPEX anticipated beyond ongoing Rs. 10-12 crores spread over FY ‘25 and into next year for upgrades and regulatory compliance. Export to domestic sales ratio: base business maintains 70% ex

Current/ Expected Orderbook/ Pending Orders?

The Prague joint venture is partially operational with one small order executed in the European region. Full operational speed for the Prague project is expected by end of August or September 2024, which will reflect in the order flow. The company is currently in discussions for potential customers in Europe, Middle East (Saudi Arabia, UAE), and some African countries, but these opportunities are preliminary and impacted by logistics issues. Hindustan Antibiotics Limited (HAL) joint venture is on track for commercial operations starting mid-October 2024. No specific numeric order book or pendi

Sanjiv.Parant.Q1 FY25Pharmaceuticals & Biotechnology

Sanjiv.Parant. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹165P/E: 27.7Market Cap: ₹208 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Base business expected to grow at approximately 25% year-on-year.
HAL joint venture projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26.
Prague joint venture operational with initial orders executed; full operational capacity expected by end of August or September 2024.
Growth from strategic partnerships with five state PSUs and potential expansion via Public-Private Partnership (PPP) models.
Expansion into new geographies including Africa, Central America, Middle East, and Latin America.
Focus on complex products and higher value-addition segments, with plans to grow injectable segment alongside nutraceuticals via Prague.
Logistics and geopolitical uncertainty (e.g., Middle East tensions) present challenges affecting order flow and costs.
No major immediate funding required; prior preferential raise funded January 2024 projects.

Margin guidance

Category 3

Base business expected to grow at approximately 25% year-on-year.
HAL JV projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26.
Prague JV operational with order flow expected to increase post logistical issues resolution; guidance uncertain due to logistics.
EBITDA margins impacted currently by high logistics costs but expected to improve as issues resolve.
No major incremental CAPEX anticipated beyond ongoing Rs. 10-12 crores spread over FY ‘25 and into next year for upgrades and regulatory compliance.
Export to domestic sales ratio: base business maintains 70% export, 30% domestic; with HAL JV, company aims for a balanced 50:50.
Challenges include geopolitical risks like Middle East tensions impacting logistics and markets.
Profit growth supported by strategic partnerships, product portfolio expansion, geographic diversification, and therapeutic area expansion in oncology and hormones (long-term).

See what Sanjiv.Parant. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Currently, Sanjivani Paranteral Limited has no debt on its books and plans to maintain a debt-free status.
There are no ongoing plans or requirements for new debt funding.
Regarding equity or other funding for future investments, no additional funds are needed at present.
Recent projects mentioned were funded earlier in January through a preferential equity raise, as disclosed in Stock Exchange documents.
No immediate fundraising activities are planned since existing funds cover current projects, and no new opportunities requiring funding have been identified.

Order book

The Prague joint venture is partially operational with one small order executed in the European region.
Full operational speed for the Prague project is expected by end of August or September 2024, which will reflect in the order flow.
The company is currently in discussions for potential customers in Europe, Middle East (Saudi Arabia, UAE), and some African countries, but these opportunities are preliminary and impacted by logistics issues.
Hindustan Antibiotics Limited (HAL) joint venture is on track for commercial operations starting mid-October 2024.
No specific numeric order book or pending orders disclosed; the company highlighted uncertainty mainly due to logistics impacting Prague order flow.
The company expects order flow to improve as logistical issues resolve and new partnerships or government projects materialize later in FY 2025.

See what Sanjiv.Parant. management said on order book — free account, 30 seconds.

Capex plans

The company currently does not require additional funds for projects; recent investments were raised through a preferential raise in January.
For the base business growth (around 20-25% YoY), no major incremental CAPEX is expected beyond ongoing maintenance and upgrades.
Planned CAPEX of Rs. 10-12 crores is for basic upgrades and regulatory inspections, spread over this and next financial year, not as an annual recurring expense.
The HAL Joint Venture has a development timeline of 9-12 months for production start, with commercial operations expected by October 2024.
The Prague JV is partially operational, with full-scale operations anticipated by end of August or September 2024.
The company is exploring strategic partnerships, mainly with government PSUs and potential collaborations in oncology and hormone therapeutic areas, though no immediate new collaborations confirmed.

Track Sanjiv.Parant. — get its next earnings analysis in your feed

How does Sanjiv.Parant. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSanjiv.Parant.

Rev 2Mar 3

See where Sanjiv.Parant. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sanjiv.Parant. rank in Pharmaceuticals & Biotechnology?

Compare Sanjiv.Parant. against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Sanjiv.Parant.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →